급성 골수성 백혈병 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 화학요법별, 지역별, 경쟁별 세분화(2020-2030년)
Acute Myeloid Leukemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Chemotherapy, By Region, and Competition, 2020-2030F
상품코드:1886542
리서치사:TechSci Research
발행일:2025년 12월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 급성 골수성 백혈병(AML) 시장은 2024년에 15억 6,000만 달러로 평가되며, 2030년까지 CAGR 8.90%로 성장하며, 26억 3,000만 달러에 달할 것으로 예측됩니다. 급성골수성백혈병(AML)은 비정상적인 골수모세포의 비정상적인 증식을 특징으로 하는 혈액 및 골수의 급속한 진행성 암입니다. AML 치료제 시장은 주로 전 세계에서 이 질환의 발병률 증가와 진단 위험이 높은 고령 인구 증가에 의해 주도되고 있습니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
15억 6,000만 달러
시장 규모 : 2030년
26억 3,000만 달러
CAGR : 2025-2030년
8.90%
가장 빠르게 성장하는 부문
호르몬 요법
최대 시장
북미
주요 시장 성장 촉진요인
급성골수성백혈병(AML) 세계 시장은 AML 연구 및 치료 기술의 지속적인 발전에 힘입어 크게 성장하고 있습니다. 이러한 혁신은 새로운 약물 계열과 치료 전략을 통해 치료 옵션을 확장하고 환자들의 치료 결과를 개선하고 있습니다.
주요 시장 과제
첨단 치료 요법에 따른 막대한 비용은 세계 급성 골수성 백혈병 시장 성장에 큰 장벽으로 작용하고 있습니다. 이러한 높은 비용은 환자의 생명을 구할 수 있는 치료법에 대한 접근성에 직접적인 영향을 미치고, 결과적으로 혁신적인 치료법의 전반적인 보급과 매출 잠재력을 제한하고 있습니다.
주요 시장 동향
경구용 약물 및 외래 치료 요법의 사용 증가는 환자의 편의성을 높이고 병원 인프라에 대한 부담을 줄임으로써 전 세계 급성골수성백혈병 시장을 크게 변화시키고 있습니다. 이러한 혁신적인 접근 방식은 보다 제한이 적은 환경에서 치료를 시행할 수 있게 하여, 특히 고령자 및 동반 질환을 가진 환자의 삶의 질을 향상시키고 있습니다.
The Global Acute Myeloid Leukemia Market, valued at USD 1.56 Billion in 2024, is projected to experience a CAGR of 8.90% to reach USD 2.63 Billion by 2030. Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow, characterized by the uncontrolled proliferation of abnormal myeloid blast cells. The market for AML therapies is primarily driven by the increasing global incidence of this disease, coupled with an expanding geriatric population which faces a higher risk of diagnosis.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 1.56 Billion
Market Size 2030
USD 2.63 Billion
CAGR 2025-2030
8.90%
Fastest Growing Segment
Hormonal therapy
Largest Market
North America
Key Market Drivers
The global Acute Myeloid Leukemia market is significantly propelled by continuous advancements in AML research and therapeutic technologies. These innovations expand treatment options and improve patient outcomes through novel drug classes and therapeutic strategies. For instance, according to The Leukemia & Lymphoma Society, in December 2024, the U. S. Food and Drug Administration approved revumenib, the first-in-class menin inhibitor for adults and children with advanced acute myeloid leukemia presenting KMT2A gene translocations.
Key Market Challenges
The substantial cost associated with advanced therapeutic regimens presents a significant impediment to the growth of the Global Acute Myeloid Leukemia Market. These high expenses directly affect patient access to potentially life-saving treatments, thereby limiting the overall uptake and revenue potential of innovative therapies. Advanced options, such as novel targeted agents and allogeneic stem cell transplantation, carry considerable price tags that can strain healthcare systems and individual patient finances globally.
Key Market Trends
The increasing utilization of oral and outpatient treatment regimens is significantly reshaping the global Acute Myeloid Leukemia market by enhancing patient convenience and reducing the burden on hospital infrastructure. These innovative approaches enable treatment administration in less restrictive settings, improving the quality of life for patients, particularly the elderly or those with comorbidities.
Key Market Players
Bristol-Myers Squibb Company (Celgene Corporation)
Novartis AG
Genmab AS
Otsuka Holdings Co. Ltd
Sanofi-Aventis (Genzyme Corporation)
Teva Pharmaceutical (Cephalon Inc.)
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sunesis Pharmaceuticals Inc.
Astellas Pharma
Oncolyze Inc.
Report Scope:
In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Acute Myeloid Leukemia Market, By Chemotherapy:
Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-metabolites
Tyrosine Kinase Inhibitors
Hormonal therapy
Other chemotherapies
Acute Myeloid Leukemia Market, By Region:
Asia Pacific
China
India
Japan
Australia
South Korea
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Middle East & Africa
South Africa
Saudi Arabia
UAE
South America
Brazil
Argentina
Colombia
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Acute Myeloid Leukemia Market.
Available Customizations:
Global Acute Myeloid Leukemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Acute Myeloid Leukemia Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal therapy, Other chemotherapies)
5.2.2. By Region
5.2.3. By Company (2024)
5.3. Market Map
6. North America Acute Myeloid Leukemia Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Chemotherapy
6.2.2. By Country
6.3. North America: Country Analysis
6.3.1. United States Acute Myeloid Leukemia Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Chemotherapy
6.3.2. Canada Acute Myeloid Leukemia Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Chemotherapy
6.3.3. Mexico Acute Myeloid Leukemia Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Chemotherapy
7. Europe Acute Myeloid Leukemia Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Chemotherapy
7.2.2. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Acute Myeloid Leukemia Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Chemotherapy
7.3.2. France Acute Myeloid Leukemia Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Chemotherapy
7.3.3. United Kingdom Acute Myeloid Leukemia Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Chemotherapy
7.3.4. Italy Acute Myeloid Leukemia Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Chemotherapy
7.3.5. Spain Acute Myeloid Leukemia Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Chemotherapy
8. Asia Pacific Acute Myeloid Leukemia Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Chemotherapy
8.2.2. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Acute Myeloid Leukemia Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Chemotherapy
8.3.2. India Acute Myeloid Leukemia Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Chemotherapy
8.3.3. Japan Acute Myeloid Leukemia Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Chemotherapy
8.3.4. South Korea Acute Myeloid Leukemia Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Chemotherapy
8.3.5. Australia Acute Myeloid Leukemia Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Chemotherapy
9. Middle East & Africa Acute Myeloid Leukemia Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Chemotherapy
9.2.2. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Acute Myeloid Leukemia Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Chemotherapy
9.3.2. UAE Acute Myeloid Leukemia Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Chemotherapy
9.3.3. South Africa Acute Myeloid Leukemia Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Chemotherapy
10. South America Acute Myeloid Leukemia Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Chemotherapy
10.2.2. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Acute Myeloid Leukemia Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Chemotherapy
10.3.2. Colombia Acute Myeloid Leukemia Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Chemotherapy
10.3.3. Argentina Acute Myeloid Leukemia Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Chemotherapy
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Acute Myeloid Leukemia Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Bristol-Myers Squibb Company (Celgene Corporation)
